SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the low priced stocks to buy with high upside potential. On December 8, Wave ...

atai Life Sciences announces Phase 2 study of EMP-01 for social anxiety disorder, with results expected in Q1 2026. atai Life Sciences has announced the dosing of the first patient in a Phase 2 study ...

SELLAS Life Sciences (SLS) provided an update on the ongoing Phase 3 REGAL trial evaluating GPS as a potential maintenance therapy in patients ...

atai Life Sciences initiates Phase 2 trial for VLS-01, a treatment for treatment-resistant depression, with results expected in 2026. Atai Life Sciences has initiated the Phase 2 Elumina trial to ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held ...

SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML ...

Earlier in December 2025, SELLAS Life Sciences Group reported Phase 2 data showing its investigational drug SLS009, combined with azacitidine and venetoclax, achieved a 46% overall response rate in ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...